AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31605794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pembrolizumab and TRT
Number of subjects: 38
Study 31397298 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 159
Study 31397298 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported BMI
Number of subjects: 159
Study 31397298 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported height
Number of subjects: 159
Study 31397298 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured BMI
Number of subjects: 159
Study 28715535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforming Opioid Prescribing in Primary Care (TOPCARE) intervention including nurse care management, electronic registry, 1-on-1 academic detailing, and electronic decision tools for safe opioid prescribing
Number of subjects: 985
Study 28715535 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPCARE intervention
Number of subjects: 985
Study 28715535 — intervention group
Group type: COMPARATOR
Intervention: Control group received electronic decision tools only
Number of subjects: 985
Study 26062091 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drop of fluorescein solution (20 mg/mL) administered to the right eye
Number of subjects: 18
Study 26062091 — intervention group
Group type: COMPARATOR
Intervention: Ocular mist (10 μL) of fluorescein solution (20 mg/mL) applied to the left eye
Number of subjects: 18
Study 23428214 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 198
Study 23428214 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 198
Study 21654252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical protocol (sustained submaximal anal and pelvic floor exercises)
Number of subjects: 72
Study 21654252 — intervention group
Group type: COMPARATOR
Intervention: Alternative group (rapid squeeze plus sustained submaximal exercises)
Number of subjects: 72
Study 21654252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exercise compliance
Number of subjects: 72
Study 19699858 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote surveillance technology with continuous ambulatory monitoring of the atrial electrogram for anticoagulation management.
Number of subjects: 227
Study 19699858 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical management for anticoagulation decision-making.
Number of subjects: 227
Study 16722841 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 15
Study 16722841 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 75 mg
Number of subjects: 15
Study 16722841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15813475 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progesterone
Number of subjects: 52
Study 15813475 — intervention group
Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 52
Study 11182260 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmChek sweat patch
Number of subjects: 0
Study 11182260 — intervention group
Group type: COMPARATOR
Intervention: Normal hygiene and cleaning procedures
Number of subjects: 0
Study 9480227 — intervention group
Group type: EXPERIMENTAL
Intervention: Placentas from Płock's area
Number of subjects: 226
Study 9480227 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placentas from Kutno)
Number of subjects: 226
Study 7942084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins only (group A)
Number of subjects: 160
Study 7942084 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin releasing hormone analog plus gonadotropins (group B)
Number of subjects: 160
Study 7942084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins only (group A) with low progesterone levels (< or = 1 ng/ml)
Number of subjects: 160
Study 3061183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. over 4-8 weeks
Number of subjects: 46
Study 3061183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31395858 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16
Study 31395858 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during overfeeding (OF)
Number of subjects: 16
Study 31395858 — intervention group
Group type: COMPARATOR
Intervention: Low energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16
Study 31395858 — intervention group
Group type: COMPARATOR
Intervention: Medium energy turnover (ET) during caloric restriction (CR)
Number of subjects: 16
Study 31395858 — intervention group
Group type: COMPARATOR
Intervention: Low energy turnover (ET) during overfeeding (OF)
Number of subjects: 16
Study 31395858 — intervention group
Group type: COMPARATOR
Intervention: Medium energy turnover (ET) during overfeeding (OF)
Number of subjects: 16
Study 27496336 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 (sucroferric oxyhydroxide)
Number of subjects: 213
Study 27496336 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride
Number of subjects: 213
Study 27496336 — intervention group
Group type: COMPARATOR
Intervention: Both PA21 and Sevelamer
Number of subjects: 213
Study 25488826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein SNPs (rs4588‐A)
Number of subjects: 3275
Study 25488826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D‐binding protein SNPs (rs7041‐T)
Number of subjects: 3275
Study 25488826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D metabolism score
Number of subjects: 3275
Study 25488826 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP (rs6013897‐A)
Number of subjects: 3275
Study 25488826 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP27B1 SNP (rs10877012‐T)
Number of subjects: 3275
Study 23395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfilcon A
Number of subjects: 36
Study 23395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Etafilcon A
Number of subjects: 36
Study 23395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Senofilcon A, Lotrafilcon B, Balafilcon A
Number of subjects: 36
Study 23395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens wear
Number of subjects: 36
Study 23395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens modulus and edge shapes (knife and chisel)
Number of subjects: 36
Study 21575826 — intervention group
Group type: EXPERIMENTAL
Intervention: FACE Advance Care Planning intervention
Number of subjects: 80
Study 21575826 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living Control group
Number of subjects: 80
Study 21575826 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates
Number of subjects: 80
Study 19928724 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Nd:YAG laser anterior capsulotomy
Number of subjects: 23
Study 19928724 — intervention group
Group type: COMPARATOR
Intervention: Two-stage continuous curvilinear capsulorhexis (CCC)
Number of subjects: 23
Study 17021422 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (300 ml)
Number of subjects: 198
Study 17021422 — intervention group
Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 198
Study 14738654 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives
Number of subjects: 19
Study 14738654 — intervention group
Group type: COMPARATOR
Intervention: Senior House Officers (SHOs)
Number of subjects: 19
Study 14738654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 11380417 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Number of subjects: 67
Study 11380417 — intervention group
Group type: COMPARATOR
Intervention: Marrow
Number of subjects: 67
Study 9160360 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine infusion
Number of subjects: 0
Study 9160360 — intervention group
Group type: COMPARATOR
Intervention: CABG group
Number of subjects: 0
Study 8106650 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily for 6 weeks)
Number of subjects: 178
Study 8106650 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg once daily for 6 weeks)
Number of subjects: 178
Study 3492156 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of propofol at 54 micrograms X kg‐1 X min‐1 (group 1)
Number of subjects: 0
Study 3492156 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of propofol at 108 micrograms X kg‐1 X min‐1 (group 2)
Number of subjects: 0
Study 3492156 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation to decrease arterial PCO2 to awake value
Number of subjects: 0
Study 30155865 — intervention group
Group type: EXPERIMENTAL
Intervention: TrueCPR device
Number of subjects: 65
Study 30155865 — intervention group
Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 65
Study 28693976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry 360 distance learning quality improvement program
Number of subjects: 626
Study 28693976 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 626
Study 25873529 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible self-adherent absorbent dressing coated with a soft silicone layer
Number of subjects: 100
Study 25873529 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 100
Study 23524149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at a rate of 0.4 μg kg(‐1) h(‐1)
Number of subjects: 100
Study 23524149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 100
Study 23524149 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 100
Study 21406694 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting
Number of subjects: 30
Study 21406694 — intervention group
Group type: COMPARATOR
Intervention: Emollient cream
Number of subjects: 30
Study 19134170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to usual GP care
Number of subjects: 0
Study 19134170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling in addition to usual GP care
Number of subjects: 0
Study 19134170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and counselling arms split into two groups to explore different treatment regimens
Number of subjects: 0
Study 19134170 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17264030 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial-cephalic arteriovenous fistula
Number of subjects: 13
Study 17264030 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radial-cephalic arteriovenous fistula
Number of subjects: 13
Study 17264030 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow brachiocephalic fistulas
Number of subjects: 13
Study 15313358 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5103
Study 15313358 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5103
Study 15313358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 5103
Study 15313358 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (BMS)
Number of subjects: 5103
Study 15313358 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-based paclitaxel-eluting stents
Number of subjects: 5103
Study 15313358 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stents (BMS)
Number of subjects: 5103
Study 15313358 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-polymer-based paclitaxel-eluting stents
Number of subjects: 5103
Study 15313358 — intervention group
Group type: COMPARATOR
Intervention: Non-polymer-based paclitaxel-eluting stents (BMS)
Number of subjects: 5103
Study 11369685 — intervention group
Group type: EXPERIMENTAL
Intervention: Short oral anticoagulant course (3 months for P-DVT/PE; 6 weeks for C-DVT)
Number of subjects: 736
Study 11369685 — intervention group
Group type: COMPARATOR
Intervention: Long oral anticoagulant course (6 months for P-DVT/PE; 12 weeks for C-DVT)
Number of subjects: 736
Study 11369685 — intervention group
Group type: EXPERIMENTAL
Intervention: Short oral anticoagulant course
Number of subjects: 736
Study 11369685 — intervention group
Group type: COMPARATOR
Intervention: Long oral anticoagulant course
Number of subjects: 736
Study 9272331 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccines
Number of subjects: 0
Study 9272331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 0
Study 8490744 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 60
Study 8490744 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 60
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 100 mg/d
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 200 mg/d
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol 300 mg/d
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/d
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/d
Number of subjects: 6
Study 2890669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 6
Study 2890669 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 30103679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 mcg/Kg bolus followed by 1 mcg/Kg/hour for 90 min)
Number of subjects: 42
Study 30103679 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (Control group)
Number of subjects: 42
Study 26718688 — intervention group
Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered subcutaneously (SQ) at a concentration of 10(4.7) plaque‐forming units (pfu)
Number of subjects: 56
Study 26718688 — intervention group
Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered intramuscularly (IM) at 10(3.4) pfu (IM Group 1)
Number of subjects: 56
Study 26718688 — intervention group
Group type: EXPERIMENTAL
Intervention: RVF MP‐12, administered IM at 10(4.4) pfu (IM Group 2)
Number of subjects: 56
Study 26718688 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo Group)
Number of subjects: 56
Study 26718688 — intervention group
Group type: EXPERIMENTAL
Intervention: RVF MP‐12 (all groups)
Number of subjects: 56
Study 24581321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation intervention (patient education focusing on pain behaviour and pain coping)
Number of subjects: 96
Study 24581321 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study 24581321 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation intervention
Number of subjects: 96
Study 22965404 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic irrigation and oral antibiotics (1 L of tap water daily and a 1-week course of ciprofloxacin and metronidazole)
Number of subjects: 50
Study 22965404 — intervention group
Group type: COMPARATOR
Intervention: 4% formalin application (for 3 minutes)
Number of subjects: 50
Study 20944503 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (8, 16, and 24 mg)
Number of subjects: 8
Study 20944503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20944503 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 8, 16, and 24 mg)
Number of subjects: 8
Study 18977988 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 338
Study 18977988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (co-trimoxazole 15 mg/kg per day or co-amoxiclav 15 mg/kg per day for 12 months)
Number of subjects: 338
Study 18977988 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (co-trimoxazole or co-amoxiclav)
Number of subjects: 338
Study 16209161 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.3%
Number of subjects: 214
Study 16209161 — intervention group
Group type: COMPARATOR
Intervention: Adapalene gel 0.1%
Number of subjects: 214
Study 16209161 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 214
Study 11834535 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoALP
Number of subjects: 110
Study 11834535 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study 11834535 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperALP
Number of subjects: 110
Study 11834535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemic subjects (n=559)
Number of subjects: 110
Study 10518234 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 intramuscular methotrexate on day 1
Number of subjects: 108
Study 10518234 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms vaginal misoprostol on day 1
Number of subjects: 108
Study 10518234 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 intramuscular methotrexate followed by 800 micrograms vaginal misoprostol 3 days later
Number of subjects: 108
Study 7898846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monophasic oral contraceptives (OCs)
Number of subjects: 87
Study 7898846 — intervention group
Group type: COMPARATOR
Intervention: No OCs or other hormonally active medications
Number of subjects: 87
Study 1456487 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with wheat flour
Number of subjects: 26
Study 1456487 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study 6697889 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-release tablet containing carbinoxamine maleate 8 mg and pseudoephedrine hydrochloride 120 mg
Number of subjects: 94
Study 6697889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 6697889 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-release tablet
Number of subjects: 94
Study 31230110 — intervention group
Group type: EXPERIMENTAL
Intervention: Full squat training (FST)
Number of subjects: 17
Study 31230110 — intervention group
Group type: COMPARATOR
Intervention: Half squat training (HST)
Number of subjects: 17
Study 29764341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 45
Study 29764341 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy (GPT)
Number of subjects: 45
Study 29764341 — intervention group
Group type: COMPARATOR
Intervention: Control (non-specific factors in GPT)
Number of subjects: 45
Study 24898552 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106
Study 24898552 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 106
Study 22596242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Registration (CR)
Number of subjects: 1065
Study 22596242 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reporting
Number of subjects: 1065
Study 22596242 — intervention group
Group type: COMPARATOR
Intervention: BCQ (gold standard)
Number of subjects: 1065
Study 19170164 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume-apheresis (LVA)
Number of subjects: 226
Study 19170164 — intervention group
Group type: COMPARATOR
Intervention: Control (group-A and group-B)
Number of subjects: 226
Study 19170164 — intervention group
Group type: COMPARATOR
Intervention: Control (group-B)
Number of subjects: 226
Study 17250613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 1,200 mg)
Number of subjects: 35
Study 17250613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 17250613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 35
Study 15748221 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for elevated levels of homocysteine
Number of subjects: 0
Study 15748221 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperhomocysteinemia
Number of subjects: 0
Study 12634571 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units injected subcutaneously)
Number of subjects: 48
Study 9682390 — intervention group
Group type: EXPERIMENTAL
Intervention: SB DTaP vaccine
Number of subjects: 0
Study 9682390 — intervention group
Group type: EXPERIMENTAL
Intervention: CB DTaP vaccine
Number of subjects: 0
Study 7800902 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg p.o. plus metoclopramide 10 mg p.o. (metoclopramide group, n = 322)
Number of subjects: 637
Study 7800902 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg p.o. (control group, n = 315)
Number of subjects: 637
Study 7800902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (metoclopramide and control)
Number of subjects: 637
Study 7800902 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of patients with and without nausea
Number of subjects: 637
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (YOH) 0.8 mg/kg
Number of subjects: 16
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 10 mg/kg
Number of subjects: 16
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 0.3 mg/kg
Number of subjects: 16
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 100 micrograms
Number of subjects: 16
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 200 micrograms
Number of subjects: 16
Study 3153710 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 16
Study 31822251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (doses not specified)
Number of subjects: 4016
Study 31822251 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility-weighted mRS scores derived from the study
Number of subjects: 4016
Study 31822251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment
Number of subjects: 4016
Study 29182412 — intervention group
Group type: EXPERIMENTAL
Intervention: Water loading (100 ml/kg for Days 1-3, 15 ml/kg on Day 4)
Number of subjects: 21